Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.55Last Year’s EPS
-1.76Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 20, 2025
|% Change Since: -16.45%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with significant achievements such as FDA approval and sales growth of FILSPARI, expansion plans into FSGS indication, and strong financial performance. However, challenges remain with declining sales of Thiola due to generic competition and a substantial net loss for the year.Company Guidance
During the Travere Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call, significant progress and strategic priorities were discussed. FILSPARI's net sales grew nearly 40% in Q4 compared to Q3, driven by its full FDA approval for IgA nephropathy and increased demand. The company plans to submit a supplemental New Drug Application (sNDA) for an FSGS indication by the end of Q1 2025, supported by data from the DUPLEX and DUET studies. FILSPARI's role as a foundational therapy in IgAN was emphasized, with a focus on early treatment and lower proteinuria targets. The company also reported net product sales of $73.5 million in Q4, with FILSPARI contributing $49.6 million. Travere aims to expand FILSPARI's use and continue optimizing their pegtibatinase program for HCU. The financial outlook for 2025 includes significant growth in net product sales and disciplined investment in strategic priorities.FDA Approval and Sales Growth of FILSPARI
FILSPARI received full FDA approval for IgA nephropathy in September 2024, leading to a 40% increase in net sales in Q4 compared to Q3. This approval allowed for broader prescribing to a wider patient population.
Expansion into FSGS Indication
Plans to submit an sNDA for FILSPARI for FSGS indication by the end of Q1 2025, supported by data from DUPLEX and DUET studies. This could potentially lead to the first-ever FDA-approved therapy for FSGS.
Strong Financial Performance
2024 net product sales grew by nearly 80% compared to 2023, driven by FILSPARI's strong uptake. FILSPARI generated $49.6 million in Q4 alone, marking a 40% growth over the previous quarter.
Positive Physician Feedback
Nephrologists are showing increased interest in FILSPARI due to its non-immunosuppressive profile and effectiveness in achieving complete remission in IgA nephropathy patients.
Successful Financing
Completed a successful financing in November 2024, raising approximately $134.7 million to support strategic priorities.
---
TVTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TVTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 20, 2025 | $23.58 | $21.98 | -6.79% |
| Oct 31, 2024 | $17.76 | $17.50 | -1.46% |
| Aug 01, 2024 | $9.24 | $9.00 | -2.60% |
| May 06, 2024 | $6.55 | $6.75 | +3.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Travere Therapeutics (TVTX) report earnings?
Travere Therapeutics (TVTX) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Travere Therapeutics (TVTX) earnings time?
Travere Therapeutics (TVTX) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TVTX EPS forecast?
TVTX EPS forecast for the fiscal quarter 2025 (Q1) is -0.55.
---